Featured Research

from universities, journals, and other organizations

Gene Therapy Reverses Heart Failure In Animals

Date:
May 24, 2007
Source:
Thomas Jefferson University
Summary:
Heart researchers have used gene therapy to reverse heart failure in animals. They used a virus to carry the gene for a protein, S100A1, into the heart cells of rats with heart failure. After 18 weeks, those animals that received the gene therapy had significantly improved heart function compared to animals that did not receive the treatment. In addition, they found that the gene therapy had additive effects to standard heart failure beta-blocker drugs.

Heart researchers at the Center for Translational Medicine at Jefferson Medical College have used gene therapy to reverse heart failure in animals. In addition, they found that this gene therapy strategy had "unique and additive effects" to currently used, standard heart failure drugs called beta-blockers.

Reporting in the American Heart Association journal Circulation, researchers led by Walter J. Koch, Ph.D., director of the Center for Translational Medicine and the George Zallie and Family Laboratory for Cardiovascular Gene Therapy in the Department of Medicine at Jefferson Medical College of Thomas Jefferson University in Philadelphia, used a virus to carry the gene for a protein, S100A1, into the heart cells of rats with heart failure. The virus expressed the S100A1 gene only in heart cells and not in other organs, essentially making it a tailored therapy. After 18 weeks, those animals that received the gene therapy had significantly improved heart function compared to animals that did not receive the treatment.

Specifically, the Koch team, including Patrick Most, M.D., and Joseph Rabinowitz, Ph.D., also in Jefferson's Center for Translational Medicine, experimentally produced heart failure in the animals, which is characterized by a dramatic reduction in the heart's pumping ability. The scientists then delivered a modified adeno-associated virus (AAV) that contained the S100A1 gene to the heart's coronary arteries with the help of a novel heart-specific "gene promoter" that enabled the gene to be present only in heart cells.

The rats with heart failure were then followed for another two months, when their heart pumping function was monitored again. The animals that received the gene therapy had significantly better heart-pumping abilities compared to the pre-gene therapy level, and overall, the S100A1-treated rats had improved heart health. The researchers found this in both individual heart cells and in the whole animal as well.

The researchers also discovered that the S100A1 gene therapy changed the geometry of the heart. In heart failure, the heart tends to increase in size. The added S100A1 slowed down this process and actually reversed it.

According to Dr. Koch, who is also W.W. Smith Professor of Medicine at Jefferson Medical College, the added S100A1 appears to improve calcium signaling in heart cells, which is critical to the force of contraction of individual cells.

In another arm of the study, the scientists looked at the effects of beta-blockers alone or in combination with the S100A1 gene therapy. They found that beta-blockers only partially rescued the animals' hearts in failure and that S100A1 gene therapy alone was significantly better at improving heart function in the model. "Importantly, the combination of the two was also therapeutic and in some indices studied there were additive effects," Dr. Koch notes. "However, it should be stressed that the beta-blocker could stop progression of heart failure in this model. S100A1 gene therapy not only stopped progression but reversed damage and actually improved the heart's performance."

Last fall, Dr. Koch and his team found that increasing levels of the protein S100A1 above normal helped protect animal hearts from further damage after simulated heart attacks. In some cases, the animals' heart function hardly changed at all even when a large percentage of the heart muscle had died. At the same time, other animals with heart cells lacking the gene for the protein couldn't handle the stress of part of the heart dying and went on to develop heart failure.

S100A1, part of a larger family of proteins called S100, is primarily found at high levels in muscle, particularly the heart. Falling levels of S100A1 are critical in the loss of heart-pumping strength after a heart attack and play an important role in the progression to heart failure. Previous studies by other researchers showed that the protein was reduced by as much as 50 percent in patients with heart failure.

Several years ago, Dr. Koch and his co-workers put the human gene that makes S100A1 into a mouse, and found a resulting increase in the heart cell's ability to contract. The mouse hearts worked better and had stronger beats. In subsequent work, he and co-workers used gene therapy to restore S100A1 levels -- and heart function -- to normal in failing animal hearts.

These results have significant implications for the future therapy of heart failure in humans, Dr. Koch says. "The use of the novel gene promoter to ensure the therapeutic gene is only expressed in heart cells increases the safety of the gene therapy for human use."

Congestive heart failure affects nearly five million Americans, many of whom have poor long-term prognoses, despite recent therapeutic advances.


Story Source:

The above story is based on materials provided by Thomas Jefferson University. Note: Materials may be edited for content and length.


Cite This Page:

Thomas Jefferson University. "Gene Therapy Reverses Heart Failure In Animals." ScienceDaily. ScienceDaily, 24 May 2007. <www.sciencedaily.com/releases/2007/05/070523153023.htm>.
Thomas Jefferson University. (2007, May 24). Gene Therapy Reverses Heart Failure In Animals. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2007/05/070523153023.htm
Thomas Jefferson University. "Gene Therapy Reverses Heart Failure In Animals." ScienceDaily. www.sciencedaily.com/releases/2007/05/070523153023.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Xtreme Eating: Your Daily Caloric Intake All On One Plate

Xtreme Eating: Your Daily Caloric Intake All On One Plate

Newsy (July 30, 2014) The Center for Science in the Public Interest released its 2014 list of single meals with whopping calorie counts. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins